Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2012
12/20/2012WO2012024659A9 Antibody-based constructs directed against tyrosine kinase receptors
12/20/2012WO2012004653A8 Method for inhibition of nf-kb gene expression
12/20/2012WO2007012811A9 Prostate stem cell markers
12/20/2012US20120323164 Photodynamic therapy with phthalocyanines and radical sources
12/20/2012US20120323163 Methods of using dual-effect liposome in therapy
12/20/2012US20120322892 Oral microemulsion of elemene
12/20/2012US20120322890 Inhibition of the Survival of Bone Cancer by Cyclohexenone Compounds from Antrodia Camphorata
12/20/2012US20120322877 (bis)urea and (bis)thiorea compounds as eipgenic modulators of lysine-specific demethylase 1 and methods of treating disorders
12/20/2012US20120322868 Food products, preparation, and therapeutic methods
12/20/2012US20120322865 Sustained polypeptide expression from synthetic, modified rnas and uses thereof
12/20/2012US20120322859 MicroRNA Fingerprints During Human Megakaryocytopoiesis
12/20/2012US20120322858 Compositions and Methods for Inhibiting Expression of a Mutant Gene
12/20/2012US20120322857 Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
12/20/2012US20120322856 Method for Promoting Angiogenesis, Vascularization, or Vessel Repair or for the Inhibiting Tumor Angiogenesis
12/20/2012US20120322853 Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
12/20/2012US20120322850 Trpm-2 antisense therapy
12/20/2012US20120322848 Lna oligonucleotides and the treatment of cancer
12/20/2012US20120322844 Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
12/20/2012US20120322838 Epothilone Compounds, Preparation Method and Use Thereof
12/20/2012US20120322834 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities
12/20/2012US20120322820 Methods to inhibit tumor cell growth by using proton pump inhibitors
12/20/2012US20120322817 Combination
12/20/2012US20120322815 Pharmaceutical composition containing a3 adenosine receptor agonist
12/20/2012US20120322814 Methods of inhibiting ire1
12/20/2012US20120322810 New salts
12/20/2012US20120322806 Quinoxalinedione derivatives
12/20/2012US20120322803 Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
12/20/2012US20120322795 Biarylamide inhibitors of leukotriene production
12/20/2012US20120322793 Protein kinase inhibitors
12/20/2012US20120322792 Method and Compositions for Treating Cancer and Related Methods
12/20/2012US20120322791 PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
12/20/2012US20120322789 Organic compounds
12/20/2012US20120322785 Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
12/20/2012US20120322778 Pharmaceutical compositions
12/20/2012US20120322775 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses
12/20/2012US20120322767 Formulations of bisphosphonates and vitamin d suiutable for intermittent intramuscular and subcutaneous administration
12/20/2012US20120322757 Methods for Aloe Processing
12/20/2012US20120322755 Cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation
12/20/2012US20120322752 SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
12/20/2012US20120322743 Compositions and Methods for Diagnosing and Treating Melanoma
12/20/2012US20120322742 Therapeutics to inhibit mll-menin interaction for treating leukemia
12/20/2012US20120322741 Psma binding ligand-linker conjugates and methods for using
12/20/2012US20120322735 Modified growth hormone polypeptides
12/20/2012US20120322718 Amygels in organic solvent for biomedical applications
12/20/2012US20120322717 Compounds and assays for controlling Wnt activity
12/20/2012US20120322674 Detecting cyp24 expression level as a marker for predisposition to cancer
12/20/2012US20120321726 Berberine-containing pharmaceutical composition for inhibiting cancer stem cell growth or carcinoma metastasis and application thereof
12/20/2012US20120321723 Microvesicles (mvs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
12/20/2012US20120321715 Micelles for the solubilization of gossypol
12/20/2012US20120321714 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof
12/20/2012US20120321698 Inhalable pharmaceutical compositions
12/20/2012US20120321692 Methods and Dressings for Sealing Internal Injuries
12/20/2012US20120321678 Intra-articularly supplementation method for treating joint diseases and injuries
12/20/2012US20120321667 T cell receptor-deficient t cell compositions
12/20/2012US20120321666 T cell therapy for b cell lymphoma
12/20/2012US20120321664 Modulation of yeast-based immunotherapy products and responses
12/20/2012US20120321653 Novel chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof
12/20/2012US20120321649 Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens
12/20/2012US20120321646 Methods for Enhancing Anti-Tumor Antibody Therapy
12/20/2012US20120321645 Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins
12/20/2012US20120321643 Anti-epidermal growth factor receptor antibodies and uses thereof
12/20/2012US20120321641 Pharmaceutical composition for treating and/or preventing cancer
12/20/2012US20120321639 Methods and compositions for the inhibition of stat5 in prostate cancer cells
12/20/2012US20120321637 Combination cancer therapy with herv inhibition
12/20/2012US20120321635 Composition Containing Inhibitors of the Expression or Activity of SH3RF2 for Preventing or Treating Cancer
12/20/2012US20120321632 Neutralizing prolactin receptor antibodies and their therapeutic use
12/20/2012US20120321629 Stem cell factor inhibitor
12/20/2012US20120321628 Hepatocyte growth factor receptor antagonists and uses thereof
12/20/2012US20120321627 Bispecific anti-vegf/anti-ang-2 antibodies
12/20/2012US20120321626 Multi-specific fab fusion proteins and methods of use
12/20/2012US20120321622 Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases
12/20/2012US20120321619 Anti-c4.4a antibodies and uses thereof
12/20/2012US20120321615 Assay for Metastatic Colorectal Cancer
12/20/2012US20120321614 Antibodies to c-met
12/20/2012US20120321608 Detection of mutations in a gene associated with resistance to viral infection, oas1
12/20/2012US20120321599 Herpes virus strains
12/20/2012US20120321596 Kit for adhering biological hard tissues
12/20/2012US20120321591 Anti-angiogenic compounds
12/20/2012US20120321590 Bridged polycyclic compounds
12/20/2012US20120321583 Protein-Polymer-Drug Conjugates
12/20/2012US20120321571 Paraben compositions
12/20/2012US20120321563 Carbonic Anhydrase Targeting Agents and Methods of Using Same
12/20/2012US20120321556 Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
12/20/2012US20120321554 Plexin d1 as a target for tumor diagnosis and therapy
12/20/2012US20120321553 Ultrafiltration Concentration of Allotype Selected Antibodies for Small-Volume Administration
12/20/2012US20120321552 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
12/20/2012CA2850137A1 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon
12/20/2012CA2839755A1 Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
12/20/2012CA2839675A1 Therapeutically active compositions and their methods of use
12/20/2012CA2839616A1 Therapeutically active compositions and their methods of use
12/20/2012CA2839301A1 Nuclear receptor modulators and their use for the treatment and prevention of cancer
12/20/2012CA2838973A1 Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies
12/20/2012CA2838945A1 Glioblastoma inhibiting compounds and their use
12/20/2012CA2838741A1 Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
12/20/2012CA2838662A1 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
12/20/2012CA2837892A1 Tem8 antibodies, conjugates thereof, and their use
12/20/2012CA2832368A1 Oncolytic virotherapy for the therapy of sarcoma
12/20/2012CA2824870A1 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
12/19/2012EP2535410A1 Aptamer to fgf2 and use thereof
12/19/2012EP2535358A1 Radioactive metal-labeled anti-cadherin antibody
1 ... 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 ... 2211